TriangleNCT00051311 · OUTCOME
Median Time to Platelet Recovery
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- Full Range
- Time frame
- Up to 2 months after stem cell transplant
What was measured
Platelet recovery is defined as \>50,000 mm3 platelet cell count after transfusion.
Analysis population: Six recipients were not evaluable for platelet recovery \> 20K because their platelet count never fell below that level (n=2) or because they were receiving aggressive platelet transfusions (n=4).
Groups in this outcome
Recipient
Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells. Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD). Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
| Group | Source count |
|---|---|
| Recipient | 25 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Recipient | 13 | Not reported | 9 | 34 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9
- upper Limit
- 34
- value
- 13
- denoms
- counts
- group Id
- OG000
- value
- 25
- units
- Participants
- description
- Platelet recovery is defined as \>50,000 mm3 platelet cell count after transfusion.
- dispersion Type
- Full Range
- groups
- description
- Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells. Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD). Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
- id
- OG000
- title
- Recipient
- param Type
- MEDIAN
- population Description
- Six recipients were not evaluable for platelet recovery \> 20K because their platelet count never fell below that level (n=2) or because they were receiving aggressive platelet transfusions (n=4).
- reporting Status
- POSTED
- time Frame
- Up to 2 months after stem cell transplant
- title
- Median Time to Platelet Recovery
- type
- SECONDARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice